(NASDAQ: CDXS) Codexis's forecast annual revenue growth rate of 32.73% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Codexis's revenue in 2025 is $49,815,000.On average, 4 Wall Street analysts forecast CDXS's revenue for 2025 to be $5,437,935,888, with the lowest CDXS revenue forecast at $5,401,484,155, and the highest CDXS revenue forecast at $5,476,044,519. On average, 4 Wall Street analysts forecast CDXS's revenue for 2026 to be $6,578,875,149, with the lowest CDXS revenue forecast at $6,229,932,645, and the highest CDXS revenue forecast at $7,551,307,986.
In 2027, CDXS is forecast to generate $11,194,824,445 in revenue, with the lowest revenue forecast at $11,194,824,445 and the highest revenue forecast at $11,194,824,445.